mutant (ep) and Hps4-mutant (le) mice (7) . Finally, the HPS1 and HPS4 proteins partially colocalize in cytoplasmic vesicles of transfected melanoma cells (7) . Together, these data strongly suggest a functional relationship or interaction between the HPS1 and HPS4 proteins.
Here, we show that the human HPS1 and human HPS4 proteins are both components of a ~500 kDa M.W. complex associated with vesicles and organelles, which we named BLOC-3 (biogenesis of lysosome-related organelles complex 2). Within BLOC-3, HPS1 and HPS4 are contained in a discrete ~200 kDa M.W. module, which we term BLOC-4. It is likely that BLOC-4, and certainly BLOC-3, contain additional protein components not yet identified. Our findings indicate that, as components of BLOC-3 and BLOC-4, the HPS1 and HPS4 proteins play a coordinated role in trafficking of proteins to newly-synthesized organelles.
EXPERIMENTAL PROCEDURES
DNA constructs-Full-length human HPS1 (4) and HPS4 (7) cDNAs were cloned in the Gateway Cloning Technology (InVitrogen) entry vector pENTR3C, and the HPS1 and HPS4 cDNA cassettes were then transferred to pDEST26, a vector for N-terminal His-fusion protein expression, and subsequently to the mammalian expression vector pIREShyg2 (InVitrogen), creating pIREShyg2-HPS1 and pIREShyg2-HPS4, respectively. To express GST-HPS4 fusion protein in E. coli, we recombined pENTR3C-HPS4 with pDEST15, a vector for N-terminal GST fusion expression from a T7 promoter, creating pDEST15-HPS4.
Recombinant Protein Expression, Purification, and Antibody Production-pDEST15-HPS4
was introduced into E. coli BL21-CodonPlus-RP (Stratagene), and GST-HPS4 fusion protein was purified from inclusion bodies (23) , and used as immunogen to prepare anti-hHPS4 polyclonal antisera in rabbits and HPS4 monoclonal antibodies in mice (Covance). Monoclonal antibodies to HPS1 were described previously (24) . Monoclonal antibody to His-Tag was from Clontech.
Derivation and Transfection of ep-and le-Mutant
Mouse Melanocytes-The wild-type mouse melanocyte line, melan-a (25) and melan-ep and melan-le melanocytes (7) have been described previously. Cells were cultured in RPMI1640 (InVitrogen), supplemented with 10% heat-inactivated FBS (HyClone), 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM Lglutamine, and 200 nM TPA at 37 °C in a 10% CO 2 atmosphere. Melan-ep or melan-le melanocytes were transfected with the pIREShyg2-HPS1 and pIREShyg2-HPS4 constructs using FuGENE 6 Transfection Reagent (Roche), and stable transformants were selected in culture media containing 300 µg/ml hygromycin B. Human MNT1 melanoma cells (26) were cultured in DMEM (InVitrogen) supplemented with 20% heat-inactivated FBS, 10% AIM-V (PAN), 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, and 100 nM Napyruvate at 37 °C in a 5% CO 2 atmosphere. Cells were visualized by standard brightfield and Hoffman illumination microscopy.
Immunoblotting-Proteins were separated in 7.5% SDS-polyacrylamide and transferred to Immobilon-P membranes (Millipore). Membranes were blocked in 5% fat-free milk in PBS for weight standards (InVitrogen). For analysis of HPS4-HPS1 complexes, immunoblots of gel filtration fractions, previously probed with anti-HPS1 antibody (24) , were stripped in 100 mM 2-mercaptoethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.7 for 30 min at 50 °C, and were re-probed as described above.
RT-PCR-RNA from melan-a and melan-le melanocytes was isolated using the TRIzol reagent (Invitrogen). First strand cDNA was synthesized using SuperScript II RNase H -reverse transcriptase and oligo(dT) 25 as primer (Invitrogen). PCR was performed using equivalent amounts of melan-a and melan-le RNAs, Platinum Taq DNA polymerase (Invitrogen), and mouse Hps1 forward (5'-GACTTCCGCCTGCTCCTACTTCCT-3') and reverse (5'-GCGTGAGCAGCTCATAGCAC-3') primers derived from exons 20 and 22, respectively. To test the effect of Tris-HCl on the BLOC-3 complex, we purified the vesicular-organellar fraction from MNT1 cells using as described (24) 
RESULTS

Complementation Analysis of HPS1-Null and HPS4-Null Mouse Melanocytes-We
generated cultured melanocyte cell lines from homozygous Hps1 null-mutant (ep) and Hps4 null-mutant (le) mice, designated melan-ep and melan-le, respectively (7). As shown in Fig. 1 , compared to wild-type melan-a melanocytes, both melan-ep and melan-le melanocytes appear hypopigmented, contain relatively few melanized melanosomes, and show a wide range of melanosome sizes, including macro-melanosomes and atypical aggregates of normal-sized melanosomes (not shown), similar to those seen in the corresponding mutant mice in vivo (7).
All aspects of this abnormal phenotype appear more marked in melan-le than in melan-ep cells, even though le-mutant mice are phenotypically indistinguishable from ep-mutant mice (7, (19) (20) (21) .
We previously showed that the HPS1 protein is unexpectedly absent in tissues from Hps4-null (le-mutant) mice, as well as from Hps1-null (ep-mutant) mice (7) . As shown in These results suggest instead that either HPS4 is required for biosynthesis of HPS1, or that absence of HPS4 destabilizes HPS1.
To determine whether HPS4 is required for biosynthesis of HPS1, we over-expressed human HPS4 in Hps1-null melan-ep mouse melanocytes by stable transformation with a human HPS4 cDNA expression plasmid, and human HPS1 in Hps4-null melan-le melanocytes by transformation with a human HPS1 expression plasmid. As expected, melan-ep cells transfected with the HPS1 expression plasmid produced abundant human HPS1 protein (Fig. 2) and were complemented to a normal pigmentation and melanosomal cellular phenotype (Fig. 1) .
Likewise, melan-le cells transfected with the HPS4 expression plasmid produced abundant human HPS4 protein (Fig. 2) and were complemented to a normal cellular phenotype (Fig. 1) .
Moreover, over-expression of human HPS4 protein in transfected melan-le cells fully restored expression of endogenous HPS1 protein. In contrast, melan-ep cells transfected with the HPS4 expression plasmid produced abundant human HPS4 protein (Fig. 2) , although they of course still expressed no endogenous HPS1 protein (Fig. 2) , but showed no apparent correction of the abnormal pigmentary or melanosomal phenotype (Fig. 1) . However, melan-le cells transfected with the HPS1 expression plasmid produced abundant human HPS1 protein and showed partial correction of the abnormal cellular phenotype, presumably due to correction of the secondary HPS1 deficit in these cells. These results show clearly that HPS4 is not required for biosynthesis of HPS1 protein, but that HPS4 instead most likely stabilizes HPS1 as part of a protein complex. and immunoblotting the bound protein for HPS1 (Fig. 3) . Together, these results demonstrate that HPS1 and HPS4 are components of a protein complex in vivo.
HPS1 and HPS4 do not Interact in a Yeast Two-Hybrid System, but HPS4 Binds to Itself
To determine whether HPS1 and HPS4 interact directly, we used a yeast two-hybrid system to test interaction between full-length HPS1 and HPS4. Appropriate combinations of mouse HPS1 and HPS4 binding domain and activation domain constructs were co-transfected into yeast strain AH109 and the co-transformants were plated on SD/-Ade/-His/-Leu/-Trp. As shown in Fig.   4 , we saw no growth for any of the HPS1-HPS4-co-transformants in any combination, indicating that mouse HPS1 and HPS4 do not interact directly, at least in this yeast system. However, as shown in Fig. 4 , we observed vigorous growth and blue color for the HPS4-HPS4 combination, indicating that HPS4 monomers interact strongly with each other. We observed no apparent HPS1-HPS1 interaction. We obtained identical results using human HPS1 and HPS4 constructs (not shown). These results indicate that HPS1 and HPS4 may not interact directly, but that HPS4 self-associates to at least a dimer.
HPS1 and HPS4 are Components of a ~500 kDa Cytoplasmic Vesicular-Organellar
Complex, BLOC-3-We previously showed that HPS1 is part of a >500 kDa cytoplasmic vesicular-organellar complex and a ~200 kDa cytosolic complex (24) . To determine which of these high molecular weight HPS1 complexes contains HPS4, we re-interrogated the immunoblots used in the previous study, now using antisera to HPS4. As shown in Fig. 5A,   HPS1 and HPS4 are both contained in the same >500 kDa cytoplasmic vesicular/organellar fraction from FME melanoma cells. In contrast, the HPS4 protein was undetectable in cytosolic fractions from both FME melanoma cells (Fig. 5B) and human lymphoblastoid cells (not shown). These results demonstrate that the >500 kDa cytoplasmic vesicular-organellar complex represents BLOC-3.
A Discrete ~200 kDa HPS1-HPS4 Complex, BLOC-4, is a Module of BLOC-3-We
previously showed that treatment of the >500 kDa BLOC-3 complex with 100 mM Tris-HCl results in release of HPS1 as a ~200 kDa post-Tris HPS1 complex, which we speculated might be identical to the ~200 kDa HPS1 complex observed in the cytosol (24) . To determine whether HPS4 is also released from BLOC-3 by Tris-HCl, we re-interrogated the immunoblots used in the previous study, now using antisera to HPS4. As shown in Fig. 5C , treatment of the FME melanoma vesicular/organellar fraction with 100 mM Tris-HCl results in release of both HPS1 and HPS4 into the same ~200 kDa sub-fractions. Thus, HPS1 and HPS4 are both released from BLOC-3 into a ~200 kDa post-Tris complex.
To determine whether HPS1 and HPS4 released from BLOC-3 by Tris-HCl reside together in a single ~200 kDa post-Tris complex or in two different ~200 kDa post-Tris complexes, we tested whether HPS1 and HPS4 could still be co-immunoprecipitated after dissociation from BLOC-3 by 100 mM Tris-HCl. As shown in Figure 6 , treatment of the vesicular/organellar fraction of MNT1 melanoma cells with Tris-HCl did not affect subsequent coimmunoprecipitation of HPS1 and HPS4, indicating that these two proteins are released from BLOC-3 in a single ~200 kDa post-Tris complex that we designate BLOC-4. BLOC-4 thus represents a discrete module of BLOC-3, and is clearly distinct from the ~200 kDa cytosolic HPS1 complex, which does not contain HPS4 (Fig. 5B ) and which we tentatively designate as BLOC-5. The fractionation scheme and relationship of BLOC-3, BLOC-4, and BLOC-5 is shown in Fig. 7 .
DISCUSSION
HPS is a group of autosomal recessive diseases associated with defective biogenesis of a specific group of organelles: melanosomes, lysosomes, platelet dense granules, and certain other granular elements. This unique constellation of related disorders suggests that there must be specific biosynthetic pathways particular to these organelles, an idea supported by recent cell biological evidence (27) . In the mouse, at least 16 different loci are associated with HPS-like phenotypes (9, 10). In humans, six genes have been associated with HPS, each corresponding to one of the mouse HPS loci (4) (5) (6) (7) (8) . These genetically defined loci provide an avenue to elucidate the physical components required for mammalian organellogenesis.
There has been considerable recent progress in understanding the relationships among these HPS-related genes, and several of the corresponding proteins have now been shown to be associated with each other in poly-protein complexes. Mouse mocha (mh)/human AP3D1 and mouse pearl (pe)/human AP3B1 both encode components of the heterotetrameric AP-3 adaptor complex (28) . Mouse pallid (pa), muted (mu), and cappuccino (cno) encode components of a novel "biogenesis of lysosome-related organelles complex", BLOC-1 (29, 30) . Very recently, we showed that mouse ruby-eye (ru)/human HPS6 and mouse ruby-eye-2 (ru2)/human HPS5 encode components of another novel complex, BLOC-2 (8) . Here, we show that the HPS1 and HPS4 proteins are components of two additional lysososome-related organellar protein complexes, BLOC-3 and BLOC-4 (Fig. 7) , and that cytosolic HPS1 appears to be part of yet another complex, BLOC-5.
Absence of HPS4 appears to result in destabilization of HPS1. Similar observations have been made for other HPS-related protein complexes. Steady-state levels of the AP-3 β3A protein are decreased in mocha (Ap3d1-mutant) as well as in pearl (Ap3b1-mutant) mice (15, 31) . Similarly, steady-state levels of the pallidin protein are reduced in both muted and reduced pigmentation (rp)-mutant mice (29) . We have shown that the HPS1 protein is absent in light ear (le) as well as pale ear (ep)-mutant mice (7) . However, the level of HPS1 protein is not reduced in pearl (pe; Ap3b1-mutant) mice and the levels of the four AP-3 component proteins are not reduced in pale-ear (ep; Hps1-mutant) mice (7), suggesting that HPS1 is not integrally associated with the AP-3 adaptor complex.
BLOC-4 appears to be a discrete HPS1-HPS4-containing module of BLOC-3 that is released by treatment with Tris-HCl. Studies using a yeast two-hybrid system indicate that HPS1 may not interact directly with HPS4, nor with itself, whereas HPS4 does interact with other molecules of HPS4. The relationship between BLOC-3 and BLOC-4, their other components, and the stoichiometry of these components, remains to be determined. In the cytosol HPS1 is contained in another ~200 kDa complex (24) that does not contain HPS4, and which thus appears to be distinct from BLOC-4. We tentatively denote this cytosolic HPS1 complex as BLOC-5.
BLOC-3 is detected in a partially purified cytoplasmic fraction that contains vesicles and organelles. We have previously shown that noncytosolic HPS1 is principally localized in uncoated small vesicles and early-stage melanosomes (24) , and that HPS4 partially co-localizes with HPS1 in vesicles and organelles (7) . BLOC-3, and its component BLOC-4, thus appear to play a key roles in trafficking newly-synthesized cargo Similar results were obtained when proteins were immunoprecipitated using polyclonal antibody to HPS4 and detected using monoclonal antibody to HPS1 (data not shown).
FIG. 7.
Fractionation schem of the BLOC-3, BLOC-4, and BLOC-5 complexes. Melanoma cell homogenate is centrifuged at 1,000 g to yield a post-nuclear supernatant that is further centrifuged at 10,000 g to yield a fraction containing large vesicles and organelles, and BLOC-3 (>500 kDa; HPS1 + HPS4). Treatment of the vesicular-organellar fraction with 100 mM Trisby guest on 
